CNS-1

Unknown Manufacturer

Generate AI report

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US 8134029 B2Applicant: JERUSSI THOMASPriority: 2010
US
12 publications
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US 2007082940 A1Applicant: SKOLNICK PHILPriority: 2005
CN
US
11 publications
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
- US 7087785 B2
  Applicant: SEPRACOR INCPriority: 2003
  US
  11 publications
- CN 100584818 C
  Applicant: SEPRACOR INCPriority: 2002
  CN
Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders
US 8071600 B2Applicant: YAMASHITA HIROSHIPriority: 2005
CN
US
9 publications
SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP 3938045 A1Applicant: SUNOVION PHARMACEUTICALS INCPriority: 2019
CN
EP
US
WO
8 publications
CRYSTALLINE FORMS OF A NEUROACTIVE STEROID
- EP 4377327 A1
  Applicant: SAGE THERAPEUTICS INCPriority: 2021
  CN
  EP
  US
  WO
  8 publications
- US 20260242410 A1
  Applicant: SAGE THERAPEUTICS INCPriority: 2022
  US
  WO
  2 publications
MOLECULAR TRANSPORT SYSTEM TO THE CENTRAL NERVOUS SYSTEM
EP 4121080 A4Applicant: STANFORD RES INST INTPriority: 2020
CN
EP
US
WO
6 publications
3-(Heteroaryl-Oxy)-2-Alkyl-1-Aza-Bicycloalkyl Derivatives As Alpha. 7-Nachrligands For TheTreatment Of Cns Diseases
US 2008194573 A1Applicant: NOVARTIS AGPriority: 2004
CN
EP
US
6 publications
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US 9458136 B2Applicant: BLACKBURN ANTHONY CPriority: 2012
CN
US
6 publications
PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
EP 4200280 A1Applicant: LILLY CO ELIPriority: 2020
CN
EP
US
WO
5 publications

Drugs

CNS-1

Patents

Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide

CRYSTALLINE FORMS OF A NEUROACTIVE STEROID